Murlentamab - CISMeF

Preferred Label : Murlentamab;

NCIt synonyms : GM102 Antibody; Anti-AMHR2 Monoclonal Antibody GM10II; Anti-AMHR2 Monoclonal Antibody GM102;

NCIt definition : An engineered, humanized, low fucose monoclonal antibody against mullerian hormone receptor II (Müllerian Inhibiting Substance Receptor II; AMHR2; AMHRII), with potential antineoplastic activity. Upon administration, murlentamab targets, binds to and inhibits AMHR2 and its downstream signaling pathways. GM102 primarily induces antibody dependent cellular cytotoxicity (ADCC) directed against AMHR2-expressing tumor cells through binding to CD16 (Fc-gammaRIIIa) that is present on immune effector cells. Decreased antibody fucosylation increases its affinity for binding to CD16 and ultimately enhances ADCC. AMHR2 is expressed in a subset of gynecological cancers.;

UNII : ZN0DUZ3M4L;

CAS number : 2058047-65-5;

Molecule name : 3C23K; GM10II; GM102; GM 102;

NCI Metathesaurus CUI : CL524747;

Details

Origin ID

C136985;

UMLS CUI

C5418189;

Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients